Compare Novo Nordisk A/S (NVO) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs TORM plc — how do they compare? Novo Nordisk A/S trades at $38.38 (market cap $165.31B), while TORM plc trades at $40.6 (market cap $4.12B). The key difference: Novo Nordisk A/S is far larger — about 40.1× TORM plc's market cap, and TORM plc pays the higher dividend (11.03%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and TORM plc for 23 Days on average.
| NVO | TRMD | |
|---|---|---|
Market Cap | $165.31B | $4.12B |
Volume | 11,432,838 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $63.98 | $41.05 |
52-Week Low | $35.29 | $19.39 |
Typical Hold Time | 116 Days | 23 Days |
Enterprise Value | $179.56B | $4.83B |
Dividend Yield | 4.71% | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
TRMD trades at $40.54, up 4.16% today, with a bullish technical signal from moving averages and strong profitability metrics including a 35.52% net income margin and 26.84% ROE. Recent earnings showed a Q2 2026 miss but a Q4 2025 beat, while 2026 revenue is projected to grow to $1.8B. A $2.40 dividend is scheduled for September 2026, and analyst consensus is unanimously bullish with 3 buy ratings.
The outlook is positive given robust fundamentals and analyst support, but risks include spot rate volatility in the tanker market and recent insider selling. Upside potential hinges on sustained freight rates, while a downturn could pressure earnings. The stock presents a value opportunity with a low P/E of 6.59, though cyclical industry exposure warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
